Member Info for David1951c

Exciting news and should bring about the much needed boost and demonstrate the confidence of the company for the future. I had to look up what is an affinity ligand.

A ligand having affinity for a target molecule is covalently attached to an insoluble support and functions as bait for capturing the target from complex solutions. The affinity ligand can be any molecule that will bind the target without also binding other molecules in the solution.

This may well interest many other biopharmas as Apta has a leadership position.

Senior figures in Destiny must be wondering what happened and surely regret issuing the RNS. Value of Bill Love's shareholding has fallen by a million plus. It shows how naive they are on the market conditions and how their advisers have also messed up.

As with too many on AIM the Mcap and SP is ridiculously low. Worth a punt so added 150k but shown as a sell.

Good news but no news on XF 73 nasal. It would have been so easy to include a few lines on progress and expectations.

Unthoughtful communication. Drop means a good entry point for buying but frustration for existing shareholders.

Followed this for some time and no doubt it could be a gamechanger with a much higher SP to come. FY results will come out in February but the investment risk is that additional funding needed would mean dilution which would be at a heavily discounted price based on current AIM market conditions. Bought 10k shares to start with and will add when possible.

A year ago the SP was 13p so a 95% decline. This shows how awful AIM has become and ceasing to function as it should. The potential is there for a re-rate if GPL can deliver. News cannot be too far away. Bought 300k shares for 0.63p but shown as a sell.

Good news. "This order significantly boosts our total Indian order book to 6.3 million units, with 3.9 million modules scheduled for delivery in accordance with the established project timelines."

Before adding to holding one major question comes up and I could not find an answer so far on their website. What is the production capacity and is further growth constrained by that?

..... is unfit for purpose. Less than 3% of shares change hands and SP drops 12%. Nonsense and no wonder Institutional Investors shy away. Volatility is unacceptable and seems skewed.

Including directors and VCTs hold around 80% of Geni and they will be very careful about fund raising and dilution as the SP has already collapsed from year highs. Hopefully any fund raise will be at a minimal discount to existing low SP but on awful AIM who knows. The potential is huge but won't be an easy ride until there is more delivery and positive news.

Yes GPL has a lot of potential and Mcap of £1m is ridiculously low. This reflects the state of the market and lack of investors with risk appetite. So many instances on AIM of fund raise with huge discounts - some every week. Interim results on 27 September stated that "The Company is currently actively seeking additional funding, both non-dilutive and equity".

I prefer to wait the outcome as funds will be needed to support rapid expansion and satisfy due diligence of major customers. This is hard on companies that expected to raise funds at sensible terms rather than on the pit the market has become.

Year end results will be due out in mid December. C4X is another example of the difficult market and SP has collapsed without any major bad news from 31p to 12p. 15 months ago £5.7m was raised at 25p and those investors are down by 50%.

In fact most of the news is good and with £15m from selling Orexin 1 the funding position should be secure for 2024. The position is not helped by lack of regular updates and retail investors are unwilling to support companies that don't value them. Bought 40k as a recovery punt but shown as a sell.

In a week's time funding and other questions will be covered in the Investor Meet session. Speculation meanwhile is a waste of time. The potential for Ondo is clear and finding backing should be easier than with most companies.

I would like to invest because it looks very promising but the issue is funding and the need to raise before the year end based on cash at 30 June and first half reduction from 31 December.

Winners are the managers and directors who recommend acceptance plus the buyers of course. They will continue to prosper.

Once again the losers are shareholders who get short changed. Only saving grace is that I have funds to invest elsewhere and hope to pick a future winner.

Hopefully the webinar and data will lead to greater institutional interest and perhaps VCTs will also take more. There are no shareholders above 10% and few above 5%. The problem is partly the share price volatility on AIM and the brutal treatment companies receive. It is no wonder IIs have little interest when SPs fluctuate so wildly and most don't have the risk appetite anymore. Mcap is less than £60m so the potential is huge if funding for P3 and other developments can be obtained.

They may need to fund raise in next six months. H1 30 June loss $8m with $4.59m cash and revenue not rising fast enough, there will be a gap to fill. AIM is brutal and companies listed are in for a hard time when seeking financial support.

There was a small article on p. 38 of The Times yesterday.

AIM is currently awful for fund raising with often huge discounts to already depressed share prices. It does not function like it once did or should. Investment risk is always there but not at this level. Investors are very wary and few companies will newly list on AIM in these conditions.

From RNS today "The Company is currently actively seeking additional funding, both non-dilutive and equity".

This hardly comes as a surprise given the capex and timescales to get sufficient revenue streams and a pity it has not been sorted earlier. Suspicion must be they have already tried but not succeeded.

Current Mcap is only £2m and after funds are raised this may become a good investment opportunity. It is too risky to buy shares until then as the dilution could be significant. AIM is a cesspit!

I have held shares for some years and increased SP is welcome. SP last September was 75p so another clear example of the brutal treatment of bio stocks (and others) on AIM. London market is broken and no wonder more companies are leaving or delisting. Why would companies try to raise in London - look at AMTE today. PIs shafted once again.